Metraipolis › archive › dc_62010ff65338

Advances in the Development of SARS-CoV-2 Mpro Inhibitors — Europe PMC PMID:35458721

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/35458721
DOI
10.3390/molecules27082523
License (as archived)
solo-consultazione
Archived
2026-10-07T15:16:12.434Z
SHA-256 of the archived text
9598cebbff6bc9b8bcddc4e02deed577cd30ded10dfa9bb6ca85a54829f046b0
Stable URL of this page
https://metraipolis.com/documento/dc_62010ff65338

How to cite

Advances in the Development of SARS-CoV-2 Mpro Inhibitors — Europe PMC PMID:35458721 — Europe PMC (en), https://europepmc.org/article/MED/35458721 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_62010ff65338 (Metraipolis archive dc_62010ff65338, sha256 9598cebbff6bc9b8bcddc4e02deed577cd30ded10dfa9bb6ca85a54829f046b0)
BibTeX
@misc{dc62010ff65338,
  title = {Advances in the Development of SARS-CoV-2 Mpro Inhibitors — Europe PMC PMID:35458721},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/35458721},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_62010ff65338; sha256 9598cebbff6bc9b8bcddc4e02deed577cd30ded10dfa9bb6ca85a54829f046b0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/35458721. Agents can read the archived copy with the MCP tool read_document.